Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00001335/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' quadrivalent influenza vaccine (GSK2282512A) compared to Sanofi Pasteur's Fluzone® Quadrivalent in children 6 to 35 months of age.
本研究旨在评估葛兰素史克生物制品（GSK Biologicals）的四价流感疫苗（GSK2282512A）与赛诺菲巴斯德（Sanofi Pasteur）的Fluzone® Quadrivalent四价流感疫苗在6至35月龄儿童中的免疫原性与安全性。
提供机构：
Vivli
创建时间：
2018-10-27
